The hallmarks of cancer immune evasion

IF 48.8 1区 医学 Q1 CELL BIOLOGY Cancer Cell Pub Date : 2024-10-10 DOI:10.1016/j.ccell.2024.09.010
Claudia Galassi, Timothy A. Chan, Ilio Vitale, Lorenzo Galluzzi
{"title":"The hallmarks of cancer immune evasion","authors":"Claudia Galassi, Timothy A. Chan, Ilio Vitale, Lorenzo Galluzzi","doi":"10.1016/j.ccell.2024.09.010","DOIUrl":null,"url":null,"abstract":"According to the widely accepted “three Es” model, the host immune system <u>e</u>liminates malignant cell precursors and contains microscopic neoplasms in a dynamic <u>e</u>quilibrium, preventing cancer outgrowth until neoplastic cells acquire genetic or epigenetic alterations that enable immune <u>e</u>scape. This immunoevasive phenotype originates from various mechanisms that can be classified under a novel “three Cs” conceptual framework: (1) <u>c</u>amouflage, which hides cancer cells from immune recognition, (2) <u>c</u>oercion, which directly or indirectly interferes with immune effector cells, and (3) <u>c</u>ytoprotection, which shields malignant cells from immune cytotoxicity. Blocking the ability of neoplastic cells to evade the host immune system is crucial for increasing the efficacy of modern immunotherapy and conventional therapeutic strategies that ultimately activate anticancer immunosurveillance. Here, we review key hallmarks of cancer immune evasion under the “three Cs” framework and discuss promising strategies targeting such immunoevasive mechanisms.","PeriodicalId":9670,"journal":{"name":"Cancer Cell","volume":null,"pages":null},"PeriodicalIF":48.8000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Cell","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ccell.2024.09.010","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

According to the widely accepted “three Es” model, the host immune system eliminates malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium, preventing cancer outgrowth until neoplastic cells acquire genetic or epigenetic alterations that enable immune escape. This immunoevasive phenotype originates from various mechanisms that can be classified under a novel “three Cs” conceptual framework: (1) camouflage, which hides cancer cells from immune recognition, (2) coercion, which directly or indirectly interferes with immune effector cells, and (3) cytoprotection, which shields malignant cells from immune cytotoxicity. Blocking the ability of neoplastic cells to evade the host immune system is crucial for increasing the efficacy of modern immunotherapy and conventional therapeutic strategies that ultimately activate anticancer immunosurveillance. Here, we review key hallmarks of cancer immune evasion under the “three Cs” framework and discuss promising strategies targeting such immunoevasive mechanisms.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症免疫逃避的特征
根据广为接受的 "三E "模式,宿主免疫系统会消灭恶性细胞前体,并在动态平衡中控制微小肿瘤,防止癌症扩散,直到肿瘤细胞发生基因或表观遗传学改变,使免疫逃逸成为可能。这种免疫侵袭表型源于各种机制,可归类为新颖的 "三C "概念框架:(1) 伪装,隐藏癌细胞,使其无法被免疫识别;(2) 胁迫,直接或间接干扰免疫效应细胞;(3) 细胞保护,使恶性细胞免受免疫细胞毒性的侵袭。阻断肿瘤细胞逃避宿主免疫系统的能力对于提高现代免疫疗法和传统治疗策略的疗效至关重要,而这些策略最终会激活抗癌免疫监视。在此,我们回顾了 "三C "框架下癌症免疫逃避的关键特征,并讨论了针对此类免疫逃避机制的前景广阔的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer Cell
Cancer Cell 医学-肿瘤学
CiteScore
55.20
自引率
1.20%
发文量
179
审稿时长
4-8 weeks
期刊介绍: Cancer Cell is a journal that focuses on promoting major advances in cancer research and oncology. The primary criteria for considering manuscripts are as follows: Major advances: Manuscripts should provide significant advancements in answering important questions related to naturally occurring cancers. Translational research: The journal welcomes translational research, which involves the application of basic scientific findings to human health and clinical practice. Clinical investigations: Cancer Cell is interested in publishing clinical investigations that contribute to establishing new paradigms in the treatment, diagnosis, or prevention of cancers. Insights into cancer biology: The journal values clinical investigations that provide important insights into cancer biology beyond what has been revealed by preclinical studies. Mechanism-based proof-of-principle studies: Cancer Cell encourages the publication of mechanism-based proof-of-principle clinical studies, which demonstrate the feasibility of a specific therapeutic approach or diagnostic test.
期刊最新文献
Integrating priorities at the intersection of cancer and neuroscience Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade IL-1 signaling in aging and cancer: An inflammaging feedback loop unveiled A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial A pan-cancer single-cell RNA-seq atlas of intratumoral B cells
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1